This is in agreement with a previous simulation analysis of plasma ALT and total bilirubin levels using DILIsym, which concluded that liver dysfunction arising from GGF2 treatment was insufficient to significantly increase total bilirubin [5]. The gene discussed is GPT; the disease is Decreased liver function.